Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 15,616 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Actinic Keratosis (AK)
Interventions: Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Cerritos, California • Fremont, California • Palm Springs, California + 14 more

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions: ATI-50002; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Alopecia
Interventions: iGrow Hair Growth System, Capillus352, HairMax Ultima 12 Lasercomb, HairMax Laserband 82; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 85 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Imipramine, Photodynamic Therapy, Actinic Keratosis
Interventions: Imipramine, Vehicle; Drug · Other
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Early Stage Breast Cancer (Stage 0-III)
Interventions: Exercise Regimen; Other
Lead sponsor: Nevada Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Herpes Labialis
Interventions: iontophoretic acyclovir; Device
Lead sponsor: Transport Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Hair Thinning
Interventions: Nutrafol Supplement capsules, Placebo capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Breast Neoplasms
Interventions: SU011248; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Breast Cancer
Interventions: Probiotic; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 28
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more

Conditions: Melanoma (Skin), Metastatic Cancer
Interventions: stereotactic radiosurgery; Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 86
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Sarcoidosis, Granuloma Annulare
Interventions: Deucravacitinib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lupus Nephritis
Interventions: BI 655064, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Plantation, Florida • Great Neck, New York • Manhasset, New York + 1 more

Conditions: Malignant Melanoma
Interventions: UV1, Sargramostim, Ipilimumab, Nivolumab; Biological
Lead sponsor: Ultimovacs ASA; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Orange, California + 16 more

Conditions: Diabetic Foot Ulcer
Interventions: Standard of care, Applications of EpiFix; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Timeline: 2012
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Breast Cancer
Interventions: Tomosynthesis digital mammography imaging system; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 2 more

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: Rigosertib Sodium, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Keloid
Interventions: Radiotherapy; Radiation
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer
Interventions: Telephone Genetic Counseling, Usual Care; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 85 Years · Female only
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York + 1 more

Conditions: Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Interventions: Transcu O2®; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: enzalutamide, anastrozole, exemestane, fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 17
States / cities: Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more

Conditions: Breast Neoplasm
Interventions: Exercise, Problem-Solving Session and Education; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Melanoma
Interventions: MelaFind; Device
Lead sponsor: MELA Sciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 487 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Englewood, Colorado • Tallahassee, Florida • Baltimore, Maryland + 3 more

Search by objective public record fields.

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Engineering Gut Microbiome to Target Breast Cancer

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Tyrosine Kinase 2 (TYK2) for GA and CS

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Radiotherapy for Keloids

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

CanRestoreFunction Cancer-related Fatigue ( CRF )

Post-Approval Study of MelaFind